ACADIA PHARMACEUTICALS INC (ACAD) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$21.98

From 52W high−30.52%

Volume6.02M

Market cap$3.66B

P/E (TTM)10.0x

P/S (TTM)3.0x

Div yield—

Key dataNov 5, 2026

Open

$21.98

From 52W high

−30.52%

Volume

6.02M

Market cap

$3.66B

ValuationView details →

P/E (Fwd)

22.8x

EV/EBITDA

19.5x

P/E (TTM)

10.0x

RSI (14)

60.9

MomentumView details →

1D Return

−1.07%

YTD Return

−16.47%

SummaryUpdated Sep 1, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a San Diego-based biopharmaceutical company founded in 1993 that specializes in developing and commercializing treatments for central nervous system disorders. The company has evolved from a research-focused organization into a commercial-stage enterprise with two marketed products addressing rare neurological conditions. ACADIA went public in 2004 and has built its business around addressing unmet medical needs in neuropsychiatric and rare disease markets, with a particular focus on conditions affecting vulnerable patient populations including those with Parkinson's disease, Rett syndrome, and other neurological disorders.

Ask drillr about ACADIA PHARMACEUTICALS INC →

ValuationView details →

P/E (Fwd)

22.8x

P/E (TTM)

10.0x

EV/EBITDA

19.5x

EV/Sales

2.3x

P/S (TTM)

3.0x

P/B (TTM)

2.6x

ProfitabilityView details →

Gross Margin

64.93%

Net Margin

30.13%

EBITDA Margin

11.67%

ROE (TTM)

26.11%

ROA (TTM)

20.19%

Asset Turnover

0.68x

GrowthView details →

Revenue YoY

+14.82%

EPS YoY

+35.67%

FCF YoY

−46.84%

Revenue CAGR 3Y

+27.48%

EPS CAGR 3Y

+69.34%

EBITDA YoY

+4.99%

MomentumView details →

1D Return

−1.07%

YTD Return

−16.47%

1Y Return

+3.05%

RSI (14)

60.9

vs 50D SMA

−3.21%

vs 200D SMA

−5.38%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

3.82x

Quick Ratio

3.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.31

EPS Surprise

55.62%

Beats (12Q)

9/12

Next Q EPS Est

$0.23

Avg Surprise (4Q)

350.77%

Rev Surprise

2.92%

Financials snapshotView financials →

Revenue (TTM)

1.20B

Net Income (TTM)

362.23M

Op. CF (TTM)

131.51M

Next earningsFeb 24, 2027 →

Latest newsMore news →

ACADIA PHARMACEUTICALS INC reported quarterly earnings of $0.31 per share, compared with $0.26 per share a year earlier.1d ago

Elizabeth H.Z. Thompson retired from her role as Acadia Pharmaceuticals' Executive Vice President and Head of Research and Development and became a consultant, effective October 23, 2026.14d ago

Similar companies

Mirxes Holding Company Limited02629.HK Xenon Pharmaceuticals Inc.XENE Shanghai Haohai Biological Technology Co., Ltd.06826.HK Jacobio Pharmaceuticals Group Co., Ltd.01167.HK AbCellera Biologics Inc.ABCL Relay Therapeutics, Inc.RLAY Find similar companies →

Latest newsMore news →

ACADIA PHARMACEUTICALS INC reported quarterly earnings of $0.31 per share, compared with $0.26 per share a year earlier.1d ago Elizabeth H.Z. Thompson retired from her role as Acadia Pharmaceuticals' Executive Vice President and Head of Research and Development and became a consultant, effective October 23, 2026.14d ago